Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU clopidogrel recall suggested after India plant fails GMP inspection

This article was originally published in The Gold Sheet

Executive Summary

The European Medicines Agency's Committee for Medicinal Products for Human Use on March 25 recommended a recall to the pharmacy level of all clopidogrel products made for the European market with active pharmaceutical ingredient that was produced by Glochem Industries at its plant in Visakhapatnam, India. Inspectors from Germany acting for EMA determined in an inspection that the plant was not compliant with EU GMPs. Swiss-based Acino Pharma markets clopidogrel, generic for Plavix, with API made from the site, as do its marketing partners A1 Pharma, Hexal, Sandoz and ratiopharm

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel